Transaction DateRecipientSharesTypePriceValue
20th January 2021Fred E Cohen20,000Exercise of derivative$13.78$275,600.00
30th December 2020Andrew Schiermeier1,500Exercise of derivative$13.48$20,220.00
17th December 2020Perry A Karsen19,000Exercise of derivative$15.78$299,820.00
17th December 2020Perry A Karsen19,000Exercise of derivative$25.98$493,620.00
17th December 2020Perry A Karsen21,978Open or private sale$52.52$1,154,284.56
17th December 2020Perry A Karsen19,000Exercise of derivative$14.35$272,650.00
17th December 2020Perry A Karsen31,764Exercise of derivative$18.00$571,752.00
17th December 2020Perry A Karsen45,450Open or private sale$53.69$2,440,210.50
17th December 2020Perry A Karsen21,336Open or private sale$54.33$1,159,184.88
1st December 2020Jose E Rivera5,000Exercise of derivative$13.88$69,400.00
Intellia Therapeutics
Intellia Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.

Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing.

Ticker: NTLA
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1652130
Employees: 270
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $362 M (0%)
Marketable Securities, Current: $75 M (-66%)
Assets, Current: $446 M (54%)
Property, Plant and Equipment, Net: $16 M (-8%)
Other Assets, Noncurrent: $5 M (57%)
Assets: $491 M (46%)
Accounts Payable, Current: $7 Th (-99%)
Accrued Liabilities, Current: $15 M (0%)
Liabilities, Current: $59 M (65%)
Common Stock, Value, Issued: $6 Th (20%)
Common Stock, Shares, Issued: $59 M (16%)
Additional Paid in Capital, Common Stock: $717 M (25%)
Retained Earnings (Accumulated Deficit): $365 M (21%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $155 Th (-40%)
Stockholders' Equity (Parent): $352 M (0%)
Liabilities and Equity: $491 M (46%)
Revenue: $16 M (-44%)
Research and Development: $38 M (-47%)
General and Administrative Expenses: $12 M (-49%)
Operating Income/Loss: $33 M (-50%)